Mesenchymal Stem Cell Expressing TRAIL as Targeted Therapy against Sensitised Tumour

Citations Over TimeTop 10% of 2018 papers

Abstract

Tapping into the ability of engineered mesenchymal stem cells (MSCs) to mobilise into the tumour has expanded the scope of cancer treatment. Engineered MSCs expressing tumour necrosis factor (TNF)-related apoptosis inducing ligand (MSC-TRAIL) could serve as a platform for an efficient and targeted form of therapy. However, the presence of cancer stem cells (CSCs) that are resistant to TRAIL and apoptosis may represent a challenge for effective treatment. Nonetheless, with the discovery of small molecular inhibitors that could target CSCs and tumour signalling pathways, a higher efficacy of MSC-TRAIL mediated tumour inhibition can be achieved. This might pave the way for a more effective form of combined therapy, which leads to a better treatment outcome. In this review, we first discuss the tumour-homing capacity of MSCs, its effect in tumour tropism, the different approach behind genetically-engineered MSCs, and the efficacy and safety of each agent delivered by these MSCs. Then, we focus on how sensitisation of CSCs and tumours using small molecular inhibitors can increase the effect of these cells to either TRAIL or MSC-TRAIL mediated inhibition. In the conclusion, we address a few questions and safety concerns regarding the utilization of engineered MSCs for future treatment in patients.

Related Papers

• → Homing and migration of mesenchymal stromal cells: How to improve the efficacy of cell therapy?(2016)454 cited
• → Journey of Mesenchymal Stem Cells for Homing: Strategies to Enhance Efficacy and Safety of Stem Cell Therapy(2012)236 cited
• → Effects of Age and Environment on Short-Term Homing and Function of Mouse Hematopoietic Stem Cells.(2010)3 cited
• Homing of Bone BMSCs and Intervention Strategies of TCM(2013)
• Homing regularity of different doses bone marrow transplantation in allogeneic hosts(2001)